p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.

Tamoxifen, a selective estrogen-receptor modulator, is effective in the treatment and prevention of breast cancer, but therapeutic resistance is common. Pure steroidal antiestrogens are efficacious in tamoxifen-resistant disease and, unlike tamoxifen, arrest cells in a state of quiescence from which they cannot reenter the cell cycle after growth factor stimulation. We now show that in hydroxytamoxifen-treated cells, transduction of the cell cycle inhibitor p27(Kip1) induces quiescence and insensitivity to growth stimulation by insulin/insulin-like growth factor I and epidermal growth factor/transforming growth factor alpha. Furthermore, reinitiation of cell cycle progression by insulin/insulin-like growth factor I in hydroxytamoxifen-arrested cells involves dissociation of the corepressors nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptor (SMRT) from nuclear estrogen receptor alpha and redistribution to the cytoplasm, a process that is inhibited by mitogen-activated protein/extracellular signal-regulated kinase, but not phosphatidylinositol 3'-kinase, inhibitors. These data suggest that agents that up-regulate p27(Kip1) or inhibit growth factor signaling via the extracellular signal-regulated kinases should be tested as therapeutic strategies in tamoxifen-resistant breast cancer.

[1]  Myles A Brown,et al.  Coregulator expression and breast cancer: improving the predictive power of estrogen receptor alpha. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[3]  J. Carroll,et al.  Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. , 2002, Cancer research.

[4]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[5]  R. Nicholson,et al.  Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. , 2001, Endocrine-related cancer.

[6]  R. Sutherland,et al.  Insulin/Insulin-like Growth Factor-I and Estrogen Cooperate to Stimulate Cyclin E-Cdk2 Activation and Cell Cycle Progression in MCF-7 Breast Cancer Cells through Differential Regulation of Cyclin E and p21WAF1/Cip1 * , 2001, The Journal of Biological Chemistry.

[7]  J. Carroll,et al.  A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence* , 2000, The Journal of Biological Chemistry.

[8]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[9]  M. Privalsky,et al.  The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.

[10]  J. Slingerland,et al.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[12]  M. Ewen,et al.  Regulation of Exit from Quiescence by p27 and Cyclin D1-CDK4 , 1998, Molecular and Cellular Biology.

[13]  V. Jordan,et al.  Basic guide to the mechanisms of antiestrogen action. , 1998, Pharmacological reviews.

[14]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Schreiber,et al.  Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.

[16]  X. Graña,et al.  pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. , 1997, Progress in cell cycle research.

[17]  J. Bartek,et al.  Abrogation of p27Kip1 by cDNA Antisense Suppresses Quiescence (G0 State) in Fibroblasts* , 1996, The Journal of Biological Chemistry.

[18]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[19]  A. Howell,et al.  Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer , 1995, The Lancet.

[20]  A. Howell,et al.  Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. , 1994, Cancer research.

[21]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[22]  R. Sutherland,et al.  Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin. , 1989, Cancer research.

[23]  R. Sutherland,et al.  Epidermal growth factor partially reverses the inhibitory effects of antiestrogens on T 47D human breast cancer cell growth. , 1987, Biochemical and biophysical research communications.